NFSG
RXRX icon

Newbridge Financial Services Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Newbridge Financial Services Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.29K Sell
1,442
-60
-4% -$200 ﹤0.01% 961
2026
Q1 		$4.61K Sell
1,502
-183
-11% -$707 ﹤0.01% 926
2025
Q4 		$6.89K Buy
1,685
+425
+34% +$2.1K ﹤0.01% 848
2025
Q3 		$6.15K Hold
1,260
– – ﹤0.01% 988
2025
Q2 		$6.38K Hold
1,260
– – ﹤0.01% 984
2025
Q1 		$6.67K Sell
1,260
-1,200
-49% -$8.75K ﹤0.01% 751
2024
Q4 		$16.6K Hold
2,460
– – ﹤0.01% 644
2024
Q3 		$16.2K Buy
2,460
+120
+5% +$860 0.01% 381
2024
Q2 		$17.6K Hold
2,340
– – 0.01% 600
2024
Q1 		$23.3K Buy
2,340
+2,140
+1,070% +$23.8K 0.01% 567
2023
Q4 		$1.97K Sell
200
-300
-60% -$2.14K ﹤0.01% 971
2023
Q3 		$3.83K Buy
+500
New +$4.99K ﹤0.01% 990

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Newbridge Financial Services Group's RXRX Position: Q2 2026 in Review

Newbridge Financial Services Group reduced its Recursion Pharmaceuticals (RXRX) stake by 4% in Q2 2026, selling an estimated $200 and leaving 1,442 shares worth $5.29K. The position accounts for ﹤0.01% of the portfolio, ranked #961.

Newbridge Financial Services Group first reported a position in RXRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $23.3K in Q1 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Newbridge Financial Services Group held 1,442 shares of Recursion Pharmaceuticals worth $5.29K as of Q2 2026.
  • Newbridge Financial Services Group sold 60 Recursion Pharmaceuticals shares in Q2 2026, an estimated $200.
  • Recursion Pharmaceuticals made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q2 2026, its #961 holding.
  • Newbridge Financial Services Group first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Newbridge Financial Services Group's Recursion Pharmaceuticals position peaked at $23.3K in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.